HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study

Journal of Clinical Virology

Volumn 72, Issue , 2015, Pages 60-65

  Bartolini, Barbara ^a   Selleri, Marina ^a   Garbuglia, Anna Rosa ^a   Giombini, Emanuela ^a   Taibi, Chiara ^a   Lionetti, Raffaella ^a   D'Offizi, Gianpiero ^a   Capobianchi, Maria R ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Diversity; HCV; NS3; Resistance associated mutations; Ultra deep pyrosequencing; Viral quasispecies

Indexed keywords

NS3 PROTEASE; PROTEINASE; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS ENZYME; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; OLIGOPEPTIDE; VIRAL PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION (PARAMETERS); GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; LIVER BIOPSY; NONHUMAN; PHYLOGENETIC TREE; PHYLOGENY; PRIORITY JOURNAL; PYROSEQUENCING; TREATMENT FAILURE; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; CASE REPORT; DRUG EFFECTS; GENETIC VARIATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; LIVER; LONGITUDINAL STUDY; PLASMA; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIVER; LONGITUDINAL STUDIES; OLIGOPEPTIDES; PLASMA; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84946409452     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.07.310     Document Type: Article

References (23)

1. Pawlotsky J.M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 2006, 299:261-284.
2. Conteduca V., Sansonno D., Russi S., Pavone F., Dammacco F. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J. Infect. 2014, 68:1-20. 10.1016/j.jinf.2013.08.019.
3. Poveda E., Wyles D.L., Mena A., Pedreira J.D., Castro-Iglesias A., et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014, 108:181-191. 10.1016/j.antiviral.2014.05.015.
4. Sullivan J.C., De Meyer S., Bartels D.J., Dierynck I., Zhang E.Z., et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin. Infect. Dis. 2013, 57:221-229. 10.1093/cid/cit226.
5. Halfon P., Locarnini S., Hepatitis C. virus resistance to protease inhibitors. J. Hepatol. 2011, 55:192-206.
6. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
7. Salvatierra K., Fareleski S., Forcada A., López-Labrador F.X. Hepatitis C virus resistance to new specifically-targeted antiviral therapy: a public health perspective. World J. Virol. 2013, 2:6-15.
8. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
9. European Association for Study of Liver EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 2014, 60:392-420. 10.1016/j.jhep.2013.11.003.
10. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009, 360:1827-1838.
11. Sullivan J.C., De Meyer S., Bartels D.J., Dierynck I., Zhang E.Z., et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin. Infect. Dis. 2013, 57:221-229.
12. Kuntzen T., Timm J., Berical A., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008, 48:1769-1778.
13. Bartels D.J., Sullivan J.C., Zhang E.Z., et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J. Virol. 2013, 87:1544-1553.
14. Robinson M., Tian Y., Delaney 4th W.E., Greenstein A.E. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:10290-10295.
15. Schneider M.D., Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing. Antiviral Res. 2014, 105:64-71. 10.1016/j.antiviral.2014.02.011.
16. Akuta N., Suzuki F., Fukushima T., Kawamura Y., Sezaki H., et al. Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. J. Clin. Microbiol. 2014, 52:193-200. 10.1128/JCM.2371-13.
17. Talal A.H., Dimova R.B., Zhang E.Z., Jiang M., Penney M.S., et al. Telaprevir-based treatment effects on hepatitis C virus in liver and blood. Hepatology 2014, 60:1826-1837. 10.1002/hep.27202.
18. Nelson C.W., Hughes A.L. Within-host nucleotide diversity of virus populations: insights from next-generation sequencing. Infect. Genet. Evol. 2015, 30:1-7. Elsevier.
19. Simen B.B., Simons J.F., Hullsiek K.H., Novak R.M., Macarthur R.D., Baxter J.D., Huang C., et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 2009, 199:693-701. 10.1086/596736.
20. Vermehren J., Susser S., Lange C.M., Forestier N., Karey U., et al. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. J. Viral Hepat. 2012, 19:120-127. 10.1111/j.1365-2893.2011.01449.x.
21. Abbate I., Vlassi C., Rozera G., Bruselles A., Bartolini B., et al. Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS 2011, 25:611-617.
22. Li W., Godzik A. Cd-hit. a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 2006, 22:1658-1659.
23. Rong L., Daharim H., Ribeiro R.M., Perelson A.S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Trans. Med. 2010, 2:1-20.